Innovation without borders, partnerships without limits
Substantial research and development (R&D) investment enables our global teams to innovate and develop next-generation diagnostic content – from ultra-sensitive detection technologies to breakthrough biomarkers for a wide range of conditions.
We also prove our innovations in practice on our own robust Lumipulse® platform, giving Contract Development & Manufacturing Organization (CDMO) partners confidence in real-world performance. As an example, our FDA-cleared biomarkers have helped make blood-based Alzheimer's disease diagnosis a reality, while our expanding neurological pipeline also covers related diseases such as multiple sclerosis (MS), Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
Most importantly, we share our innovative solutions with other technology providers through open partnerships, providing everything from diagnostic raw materials and reagents to complete development, manufacturing, and clinical and regulatory services. This collaboration creates exponential impact, multiplying our breakthroughs across diagnostic platforms, and reaching millions more patients than we could serve alone.
We reinvest revenues from these partnerships into further R&D to continuously fuel our innovation engine.
Product categories:
Products by diseases and disorders:
Healthcare for You.
With our deep involvement in human health, we aim to be a group that contributes to the development of healthcare through trust and innovation.
Insight articles
HPV genotyping in FFPE tissue: meeting the challenges of archival sample analysis
Human papillomavirus (HPV) is a necessary cause of cervical cancer and is increasingly recognized as an important etiological factor in a range of...
Clinical validation of the PreCursor-M AnoGYN test: Tailoring treatment of anal and vulvar cancer precursors
A major challenge for the correct implementation of the anal cancer screening guidelines is the generally limited availability of High-Resolution...
New trends in cervical cancer screening: Self-sampling would allow full molecular screening – great opportunity to increase attendance to cervical cancer screening
Cervical cancer screening is evolving, and one of the most promising innovations is full molecular self-screening. This method combines HPV testing...
Fujirebio introduces its Neuro Expert Toolbox (NExT) at AAIC 2025
Fujirebio is introducing its Neuro Expert Toolbox (NExT) for the first time at AAIC 2025 (Alzheimer's Association International Conference®) in...
EUROGIN 2025 – key takeaway messages
The EUROGIN 2025 conference, held at the Alfândega Congress Center in Porto, Portugal, focused on advancing scientific efforts to control HPV-related...
Updated anal cancer screening guidelines now provide a basis for expansion of screening to all at-risk populations
Screening guidelines for anal cancer prevention have traditionally focused on people with HIV, and focus on the detection of high-grade squamous...
